Inspire Medical Systems last week named Gary Ellis, the former CFO at Medtronic (NYSE:MDT), to its board of directors effective immediately. Minneapolis-based Inspire Medical also said that Amzak Health managing partner Joyce Erony left the board effective yesterday. Ellis spent 27 years at Medtronic before retiring in 2016. “On behalf of the entire Inspire board […]
apyxmedical
Apyx Medical faces investor suit over dermal resurfacing Renuvion FDA bid
Apyx Medical (NYSE:APYX) said today that it, and its CEO Charles Goodwin, are facing a suit from investors claiming it made misleading statements related to its attempt to gain a dermal resurfacing indication from the FDA for its Renuvion/J-Plasma systems. The J-Plasma device is a plasma-based cutter and coagulator that uses helium ionization to produce a […]
Apyx Medical withdraws Renuvion FDA 510(k) app for dermal resurfacing indication
Apyx Medical (NYSE:APYX), formerly known as Bovie Medical, said late yesterday that it has voluntarily withdrawn the FDA 510(k) clearance application for its J-Plasma/Renuvion device seeking a dermal resurfacing indication. The Clearwater, Fla.-based company submitted a new 510(k) clearance application seeking new indications for the Renuvion system in December. The application came supported by by […]
JenaValve names Kilcoyne as CEO | Personnel Moves – January 15, 2019
JenaValve Technology said today that it named former ReVision Optics prez & CEO John Kilcoyne as its new chief executive officer, effective immediately, replacing Dr. Victoria Carr-Brendell, who has taken up an executive leadership position with Sonova Holding AG (SIX:SOON). Prior to his time at ReVision Optics, Kilcoyne served as prez & CEO at Micrus Endovascular where he […]
Dexcom Q4 prelims top consensus | Wall Street Beat
Dexcom (NSDQ:DXCM) topped estimates on Wall Street today with preliminary results for its fourth-quarter financial results. The San Diego, Calif.-based company said it expects to report $331 million in sales for the quarter ended Dec. 31 – up at least 50% from the same period last year. Get the full story at our sister site, Drug […]
